Cargando…

Cell Line Characteristics Predict Subsequent Resistance to Androgen Receptor-Targeted Agents (ARTA) in Preclinical Models of Prostate Cancer

Treatment of prostate cancer (PCa) has changed considerably in the last decade due to the introduction of novel androgen receptor (AR)-targeted agents (ARTAs) for patients progressing on androgen deprivation therapy (ADT). Preclinical research however still relies heavily on AR-negative cell line mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moll, Jan Matthijs, Teubel, Wilma J., Erkens, Sigrun E., Jozefzoon-Agai, Ashraf, Dits, Natasja F., van Rijswijk, Angelique, Jenster, Guido W., van Weerden, Wytske M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234122/ https://www.ncbi.nlm.nih.gov/pubmed/35769712 http://dx.doi.org/10.3389/fonc.2022.877613

Ejemplares similares

Bypass Mechanisms of the Androgen Receptor Pathway in Therapy-Resistant Prostate Cancer Cell Models
por: Marques, Rute B., et al.
Publicado: (2010)

Modulation of Androgen Receptor Signaling in Hormonal Therapy-Resistant Prostate Cancer Cell Lines
por: Marques, Rute B., et al.
Publicado: (2011)

Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling
por: Moll, J. Matthijs, et al.
Publicado: (2022)

A bypass mechanism of abiraterone‐resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling
por: Moll, Jan M., et al.
Publicado: (2019)

Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling
por: Van Hemelryk, Annelies, et al.
Publicado: (2022)

Activation of c-MET Induces a Stem-Like Phenotype in Human Prostate Cancer
por: van Leenders, Geert J. L. H., et al.
Publicado: (2011)

Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer
por: Mout, Lisanne, et al.
Publicado: (2020)

Viability Analysis and High-Content Live-Cell Imaging for Drug Testing in Prostate Cancer Xenograft-Derived Organoids
por: Van Hemelryk, Annelies, et al.
Publicado: (2023)

An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective
por: Morgans, Alicia K., et al.
Publicado: (2022)

Modeling Prostate Cancer Treatment Responses in the Organoid Era: 3D Environment Impacts Drug Testing
por: Van Hemelryk, Annelies, et al.
Publicado: (2021)

Arta plastica ín Republica Populará Romíná 1944-1954.

Detection of Legionella spp. from Domestic Water in the Prefecture of Arta, Greece
por: Dimitriadi, Dimitra, et al.
Publicado: (2014)

The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research
por: Ruigrok, Eline A.M., et al.
Publicado: (2019)

Galeria Nationala, Sectia de Arta Moderna si Contemporana = The Romanian National Gallery, Modern and Contemporary Art Section /
Publicado: (1965)

Book Review: Humanism in medicine and art (Umanismul in medicina si arta) – by Ioan Zăgreanu
por: Dumitrascu, Dan
Publicado: (2017)

Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response
por: Zhang, Wenhao, et al.
Publicado: (2018)

Patient-Derived Xenograft Models in Cancer Research
por: van Weerden, Wytske M.
Publicado: (2021)

Structural factors and best practices in implementing a linkage to HIV care program using the ARTAS model
por: Craw, Jason, et al.
Publicado: (2010)

Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer models
por: van de Merbel, Arjanneke F., et al.
Publicado: (2021)

CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance
por: Langebäck, Anette, et al.
Publicado: (2019)

Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer
por: Böttcher, René, et al.
Publicado: (2015)

Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases
por: Böttcher, René, et al.
Publicado: (2016)

Continued Androgen Signalling Inhibition improves Cabazitaxel Efficacy in Prostate Cancer
por: Mout, Lisanne, et al.
Publicado: (2021)

Characterization of Heterogeneous Prostate Tumors in Targeted Pten Knockout Mice
por: Korsten, Hanneke, et al.
Publicado: (2016)

C/D-box snoRNA-derived RNA production is associated with malignant transformation and metastatic progression in prostate cancer
por: Martens-Uzunova, Elena S., et al.
Publicado: (2015)

Awe and anxiety for cancer cells: connecting scientists and patients in a holistic approach of metastasis research
por: Bronkhorst, Hildert, et al.
Publicado: (2023)

Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
por: Ruigrok, Eline A. M., et al.
Publicado: (2020)

Regulation of expression of Na(+),K(+)-ATPase in androgen-dependent and androgen-independent prostate cancer
por: Blok, L J, et al.
Publicado: (1999)

Androgen deprivation therapy and the risk of subsequent keratitis
por: Liu, Dai-Wei, et al.
Publicado: (2020)

Role of the DNA damage response in prostate cancer formation, progression and treatment
por: Zhang, Wenhao, et al.
Publicado: (2019)

Correction to: Role of the DNA damage response in prostate cancer formation, progression and treatment
por: Zhang, Wenhao, et al.
Publicado: (2019)

Androgen receptor profiling predicts prostate cancer outcome
por: Stelloo, Suzan, et al.
Publicado: (2015)

Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification
por: Matzkin, Haim, et al.
Publicado: (2019)

In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies
por: Chatalic, Kristell L.S., et al.
Publicado: (2016)

Selective androgen receptor modulators in preclinical and clinical development
por: Narayanan, Ramesh, et al.
Publicado: (2008)

Subsequent Malignant Neoplasms in Retinoblastoma Survivors
por: Fabius, Armida W. M., et al.
Publicado: (2021)

The Staphylococcus aureus pSK41 plasmid-encoded ArtA protein is a master regulator of plasmid transmission genes and contains a RHH motif used in alternate DNA-binding modes
por: Ni, Lisheng, et al.
Publicado: (2009)

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
por: Cochrane, Dawn R, et al.
Publicado: (2014)

Androgen Receptor in Breast Cancer—Clinical and Preclinical Research Insights
por: Anestis, Aristomenis, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6i6fqj5lkbomjhq5hu7dr3g5gs